When these patients were compared, neither the rate of decrease in tumor markers (CEA or CA 19–9) after NACRT, the grade of peripancreatic major vessel invasion, nor the tumor response according to the RECIST differed significantly (Table 5). The gene discussed is CEACAM5; the disease is neoplasm.